复星医药子公司与Expedition签署许可协议 最高获1.2亿美元不可退还相关款项

财中社
Aug 11

复星医药(600196/02196)发布公告,控股子公司复星医药产业于2025年8月11日与Expedition签署《许可协议》,授予Expedition在除中国境内及港澳地区外的全球范围内开发、生产及商业化在研产品XH-S004的权利。根据协议,Expedition将支付复星医药产业至多1.2亿美元不可退还的首付款和开发及监管里程碑款项,其中首付款为1700万美元,开发及监管里程碑款项的具体金额...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10